文献速递前列腺癌

18F-rhPSMA-7.3正电子发射断层扫描在疑似前列腺癌复发男性中的诊断性能与安全性:3期前瞻性多中心研究(SPOTLIGHT)结果

Diagnostic Performance and Safety of 18F-rhPSMA-7.3 Positron Emission Tomography in Men With Suspected Prostate Cancer Recurrence: Results From a Phase 3, Prospective, Multicenter Study (SPOTLIGHT).
PubMed 文献 · J Urol · 2023-04-26

SPOTLIGHT(NCT04186845)是一项3期前瞻性多中心研究,评估新型放射性杂合18F-rhPSMA-7.3 PET在389例疑似前列腺癌复发男性中的诊断性能与安全性。在366例有标准真相的患者中,验证检出率为51%至54%,超过预设阈值;但联合区域水平阳性预测值为46%至60%,未达预设阈值。在组织病理学标准真相亚组中,两项指标均超过预设阈值。未发现显著安全性问题。

要点

  • 在全部389例可评估扫描患者中,18F-rhPSMA-7.3总检出率为83%(多数读者判读)。
  • 在366例有标准真相患者中,验证检出率为51%(95% CI 46.1-56.6)至54%(95% CI 48.8-59.3),超过预设阈值。
  • 联合区域水平阳性预测值为46%(95% CI 42.0-50.3)至60%(95% CI 55.1-65.5),未达预设阈值。

核心结论

  • 18F-rhPSMA-7.3为复发性前列腺癌定位提供了具有临床意义的验证检出率。
  • 尽管未达到联合区域水平阳性预测值的共同主要终点,总体数据支持18F-rhPSMA-7.3的潜在临床效用。

研究设计与样本

  • SPOTLIGHT(NCT04186845)为3期前瞻性多中心研究,纳入疑似前列腺癌复发的男性。
  • 患者在静脉给予296±20% MBq 18F-rhPSMA-7.3后50-70分钟接受PET/CT。
  • 由3名盲法独立中心读者评估扫描,以评估共同主要终点(验证检出率和联合区域水平阳性预测值)。

主要发现

  • 在全部389例可评估扫描患者中,18F-rhPSMA-7.3总检出率为83%(多数读者判读)。
  • 在366例有标准真相(组织病理学[n=69]/仅确认性影像[n=297])的患者(中位前列腺特异性抗原1.27 ng/mL)中,验证检出率为51%(95% CI 46.1-56.6)至54%(95% CI 48.8-59.3)。
  • 联合区域水平阳性预测值在各读者间为46%(95% CI 42.0-50.3)至60%(95% CI 55.1-65.5)。
  • 在组织病理学标准真相亚组中,多数读者判读的验证检出率为81%(95% CI 69.9-89.6),联合区域水平阳性预测值为72%(95% CI 62.5-80.7)。
  • 未发现显著安全性问题。

关键数值与推荐

  • 验证检出率的预设统计阈值(置信区间下限)为36.5%。
  • 联合区域水平阳性预测值的预设统计阈值(置信区间下限)为62.5%。
  • 验证检出率等效于总检出率乘以阳性预测值。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: SPOTLIGHT (NCT04186845) evaluated diagnostic performance and safety of radiohybrid 18F-rhPSMA-7.3, a novel high-affinity positron emission tomography radiopharmaceutical. MATERIALS AND METHODS: Men with prostate cancer recurrence underwent positron emission tomography/CT 50-70 minutes after intravenous administration of 296±20% MBq 18F-rhPSMA-7.3. To assess the coprimary end points (verified detection rate and combined region-level positive predictive value), 3 blinded, independent central readers evaluated the scans. Verified detection rate is equivalent to the overall detection rate × positive predictive value. Standard of truth was established for each patient using histopathology or confirmatory imaging. Statistical thresholds (lower bounds of the confidence intervals) of 36.5% and 62.5% were prespecified for verified detection rate and combined region-level positive predictive value, respectively. Additional end points included detection rate, verified detection rate, and combined region-level positive predictive value in patients with histopathology standard of truth, and safety. RESULTS: The overall 18F-rhPSMA-7.3 detection rate among all 389 patients with an evaluable scan was 83% (majority read). Among the 366 patients (median prostate-specific antigen 1.27 ng/mL) for whom a standard of truth (histopathology [n=69]/confirmatory imaging only [n=297]) was available, verified detection rate ranged from 51% (95% CI 46.1-56.6) to 54% (95% CI 48.8-59.3), exceeding the prespecified statistical threshold. Combined region-level positive predictive value ranged from 46% (95% CI 42.0-50.3) to 60% (95% CI 55.1-65.5) across the readers, not meeting the threshold. In the subset of patients with histopathology standard of truth, the verified detection rate and combined region-level positive predictive value were both above the prespecified thresholds (majority read, 81% [95% CI 69.9-89.6] and 72% [95% CI 62.5-80.7], respectively). No significant safety concerns were identified. CONCLUSIONS: 18F-rhPSMA-7.3 offers a clinically meaningful verified detection rate for localization of recurrent prostate cancer. Despite missing the coprimary end point of combined region-level positive predictive value, the totality of the data support the potential clinical utility of 18F-rhPSMA-7.3.

来源:J Urol,查看原文。版权归原作者所有。

引用

  1. Jani AB, Ravizzini GC, Gartrell BA, et al. Diagnostic Performance and Safety of 18F-rhPSMA-7.3 Positron Emission Tomography in Men With Suspected Prostate Cancer Recurrence: Results From a Phase 3, Prospective, Multicenter Study (SPOTLIGHT). J Urol. 2023. PMID: 37126069. doi:10.1097/JU.0000000000003493

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。